






Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases

Davide Giacobino¹ | Mariateresa Camerino¹  | Federica Riccardo² |
 Federica Cavallo²  | Lidia Tarone² | Marina Martano³ | Alfredo Dentini⁴ |
 Selina Iussich¹ | Elena Lardone¹ | Paolo Franci¹ | Alberto Valazza¹ |
 Luca Manassero¹ | Sara Del Magno⁵  | Raffaella De Maria¹  |
 Emanuela Morello¹ | Paolo Buracco¹ 

¹Department of Veterinary Sciences,
University of Torino, Torino, Italy

²Department of Molecular Biotechnology and
Health Sciences, Molecular Biotechnology
Center, University of Torino, Torino, Italy

³Department of Medical Veterinary Science,
University of Parma, Italy

⁴Clinica Veterinaria Tyrus, Terni, Italy

⁵Department of Veterinary Medical Science,
University of Bologna, Italy

Correspondence

Paolo Buracco, Department of Veterinary
Sciences, University of Torino, Largo Paolo
Braccini 2, 10095 Grugliasco, Italy.
Email: paolo.buracco@unito.it

Abstract

Canine oral malignant melanoma is locally invasive and highly metastatic. At present, the best option for local control is *en bloc* excision followed by radiation if excision margins are incomplete. Adjuvantly, the role of chemotherapy is dubious while immunotherapy appears encouraging. This retrospective study evaluated 155 dogs with oral malignant melanomas (24 stage I, 54 stage II, 66 stage III and 11 stage IV) managed in a single institution. The aim was to evaluate the differences in median survival time (MST) and disease-free interval (DFI) between dogs which, at presentation, were treated surgically with a curative intent (group 1) vs those marginally excised only (group 2). MST in group 1 was longer than in group 2 (594 vs 458 days), but no significant difference was found ($P = .57$); a statistical difference was, however, found for DFI (232 vs 183 days, $P = .008$). In the subpopulation of vaccinated dogs, the impact of adjuvant anti-CSPG4 DNA electrovaccination was then evaluated (curative intent, group 3, vs marginal, group 4); a significant difference for both MST (1333 vs 470 days, respectively, $P = .03$) and DFI (324 vs 184 days, respectively, $P = .008$) was found. Progressive disease was significantly more common in dogs undergoing marginal excision than curative intent excision for both the overall population ($P = .03$) and the vaccinated dogs ($P = .02$). This study pointed out that, after staging, wide excision together with adjuvant immunotherapy was an effective approach for canine oral malignant melanoma.

KEYWORDS

adjuvant immunotherapy, CSPG4, DNA electrovaccination, dog, oral malignant melanoma, surgery

Paolo Buracco and Emanuela Morello contributed equally to the article.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *Veterinary and Comparative Oncology* published by John Wiley & Sons Ltd.

1 | INTRODUCTION

Malignant melanoma is an aggressive tumour characterized by high local invasiveness and metastatic potential in both humans and dogs. The most frequent location in dogs is the oral cavity, accounting for up to 30-40% of canine oral malignancies.¹⁻³ The biological behaviour of canine oral malignant melanoma (COMM) can be predicted based on several clinical (site of growth, size and clinical stage)²⁻⁴ as well as on histological and immunohistochemical factors (Ki67 expression, mitotic index, degree of pigmentation and nuclear atypia).^{5,6} It has also recently been shown that platelet-derived growth factor receptor expression correlated with prognosis.⁷

It has been reported that COMM invades the bone in 57.0% of cases.^{3,8} The metastatic rate is variable ranging from 30.3% to 74.0% at the level of the regional lymph nodes,^{3,9} and from 14.0% to 92.0% as distant metastatic spread (lungs and other organs).³

Factors such as the site of tumour growth (gum, internal lip/cheek, palate, tongue and tonsil), the size and degree of local soft tissue, and the bone invasion have a heavy impact on the choice of treatment for local tumour control. For local tumour control with a curative intent, a wide surgical excision should be performed. While evidence guiding specific surgical margins is lacking, the authors aim for a minimum of 1.5-2 cm of macroscopically sound tissue all around the COMM, when feasible. The reasons for an excision with no local curative intent may include difficult tumour locations (including the tongue¹⁰ and the tonsil), first excision not performed by a surgeon specialized in veterinary oncological surgery or justified as an excisional biopsy and, finally, marginal excision requested by the owner for palliation because of the signs of foul odour and bleeding from a rapidly tumour growth. Radiotherapy should be considered as adjuvant therapy for those COMMs incompletely excised or, as a primary treatment or in combination with medical treatment, for those cases deemed inoperable or when the owners refuse surgery.¹¹⁻¹⁸ An alternative to radiotherapy for local tumour control is electrochemotherapy which would be contraindicated when tumour bone erosion is already evident.¹⁹⁻²¹

Distant metastasis from COMM, more than local recurrence, represents the definitive cause of death in the majority of dogs; therefore, there is the absolute need, once local control has been reached, to adopt adjuvant systemic treatments in an attempt to delay the metastatic spread. Standard chemotherapy, based mainly on the use of carboplatin, has failed to show real efficacy when used in an adjuvant setting since survival did not appear to be prolonged significantly when compared with local tumour control only.^{13-15,22-24} For all these reasons, and also thanks to the immunogenic features of melanoma, several studies dealing with immunotherapy have been carried out. Melanoma-associated antigens have been identified (eg, Tyrosinase and Chondroitin sulphate proteoglycan 4 [CSPG4]) and utilized in producing vaccines capable of evoking an immune response against COMM.²⁵⁻³² In particular, the authors' attention was focused on CSPG4, a cellular membrane antigen, characterized by restricted distribution in normal healthy tissues and high expression on neoplastic cells in both human and canine MM. It coordinates several intracellular pathways regulating different cell functions (ie, proliferation,

migration and survival), thus being involved in tumourigenesis at multiple levels.³³⁻³⁶ In addition, CSPG4 has also been shown to be overexpressed in melanoma cancer stem cells and associated with poorer patient prognosis.^{29,37} All these features make CSPG4 an ideal antigen to be safely and effectively targeted.

The aim of this retrospective study was to evaluate a) the difference in terms of prognosis (disease-free interval [DFI] and survival time) between COMMs which, immediately after the first presentation, were treated surgically with a curative intent excision vs those marginally excised only, b) the potential relationship between the type of surgery performed and progressive disease, and c) the impact of adjuvant anti-CSPG4 DNA electrovaccination on both survival and DFI in the two groups of dogs.

2 | MATERIALS AND METHODS

2.1 | Patient enrolment

Client-owned dogs affected by COMMs which were presented at the Veterinary Teaching Hospital of Grugliasco (Turin, Italy) of the University of Turin since January 1, 2000 with a minimum follow-up of 1 year as of 30 September 2020 were retrospectively considered for this study. The dogs were presented for surgical treatment, or for anti-CSPG4 DNA electrovaccination or both after having already been operated elsewhere. Written consent was obtained from the owners for the anaesthetic, diagnostic, histological, and surgical procedures before staging. Regarding adjuvant anti-CSPG4 DNA electrovaccination, other prospective studies have been carried out since 2009^{27,28} and still others are in progress. The dogs were treated according to the Good Clinical Practice guidelines for animal clinical studies. Both the Ethics Committee of the University of Turin and the Italian Ministry of Health approved the trials (0004230-20/02/2018-DGSAF-MDS-P and 0015537-28/06/2017-DGSAF-MDS-P); specific written consent for entry into the study was obtained from all the owners of the dogs vaccinated.

2.2 | Tumour staging and treatment

Dogs were included if they had undergone a surgical excision of the primary tumour with or without regional lymphadenectomy and if histology confirmed a diagnosis of COMM. The data collected included sex, age, weight and breed as well as tumour localisation and size, and tumour-node-metastasis (TNM) classification based on Owen LN.³⁸ For both the staging and the evaluation of the general health condition, all dogs underwent a complete clinical examination, a complete blood examination (complete blood count and biochemistry) and a more specific cardiological evaluation (echocardiography or electrocardiogram or both) when indicated; imaging included X-rays of the thorax (three views) and abdominal ultrasound or total body computed tomography (CT). Dogs were excluded from the study if distant metastasis were detected before surgery. Dogs with concurrent

diseases capable of negatively influencing a minimum follow-up of 1 year (mild to severe renal, hepatic or cardiac diseases or other tumours) were also excluded. In addition, all the adjuvant treatments adopted were recorded: metronomic therapy (piroxicam + cyclophosphamide + thalidomide), standard chemotherapy (cisplatin or carboplatin), radiotherapy (hypofractionated protocol) and anti-CSPG4 DNA electrovaccination.²⁷⁻²⁹

The surgical procedure used to resect COMM, excising only the macroscopic tumour without any attempt to include any or just a few millimetres of macroscopically normal surrounding tissue, was considered to be a marginal excision. If the excision was considered to have a curative intent (for local tumour control only), an attempt was made to include at least 1.5 cm up to 2 cm of macroscopically normal bone, soft tissues or both (depending on the tumour location), independent of the result of the histological evaluation of the inked excision margins (infiltrated or non-infiltrated margins at histology). Moreover, the authors decided to consider as curative an *en bloc* resection performed immediately after a cytological evaluation or within 1 month from a previous incisional or marginal excisional biopsy.

The histological data included the evaluation of the excision margins (not infiltrated, infiltrated or unknown), the mitotic index (MI) (<4/10 high power fields [HPF] or \geq 4/10 HPF) and Ki67 expression (<19.5% or \geq 19.5%).^{5,6} All the excised regional lymph nodes were sent to the histology laboratory for evaluation; if not excised, the mandibular lymph nodes were aspirated and cytologically evaluated.

The entire population of dogs was divided and evaluated based on the type of surgery performed (group 1, curative surgery; group 2, marginal excision). Subsequently, only vaccinated dogs were considered and were divided according to the type of surgery performed (group 3, curative surgery plus electrovaccination; group 4, marginal surgery plus electrovaccination). The DNA electrovaccination procedure was performed only in dogs with COMMs which were characterized by a CSPG4 immunohistochemical expression \geq 3/8³⁷ which was selected as a cut-off value for inclusion in the immunization group. Dogs, under brief general anaesthesia, were vaccinated with plasmids coding for the CSPG4 antigen. The vaccination was started 1 to 3 weeks after surgery and was repeated after 2 weeks and then monthly for a minimum of 6 and a maximum of 24 immunizations. The CSPG4-coding plasmids (500 μ g in 200 μ L of 0.03% NaCl) were injected into the muscles of the caudal thigh and, 2 minutes later, nine electric pulses (1 high voltage, amplitude 450 V, length 50 milliseconds, frequency 3 HZ; 1 second pause; eight low-voltage amplitude 110 V, length 20 milliseconds, pause 300 milliseconds) were applied to the injection site using the CLINIPORATOR (Igea), an instrument already approved for veterinary application. The dogs were monitored for acute, late local or systemic side effects.²⁷⁻²⁹

2.3 | Patient monitoring

Vaccinated dogs received a monthly re-examination during which a clinical examination, blood examinations and a total body CT scan were performed. Dogs that were not vaccinated had re-examination every

3 months in the first year and every 6 months in the second year. At each of these re-examinations, clinical examination, blood examinations, chest radiographs and abdominal ultrasound were performed.

2.4 | Statistical analysis

The analyses were carried out using GraphPad Prism (version 9.0.0 for Windows, GraphPad Software, San Diego, California, www.graphpad.com), with statistical significance set at a $P < .05$. The data were summarized using descriptive statistics, and were indicated as mean, median and range. Distribution was checked graphically using the Shapiro-Wilk Test; the Wilcoxon Rank Sum Test was then utilized to evaluate the possible differences within the groups for age, weight, Ki67 expression, MI and clinical tumour stage. The median DFI and survival time (MST) were evaluated using the Kaplan-Meier method; the log-rank test was used to calculate the DFI and MST of the dogs in the two treatment groups (curative intent—group 1—vs marginal excision—group 2), and of the subpopulation of dogs which received the anti-CSPG4 DNA vaccination and curative intent surgery (group 3) vs vaccination and marginal surgery (group 4). The DFI was calculated from the day of surgery to the first tumour recurrence or metastasis and ST as the period from the day of surgery to the patient's death. Dogs which died from non-COMM-related causes, those lost to follow-up and those still alive at the end of the study were censored. Finally, the Fisher's exact test was used to test a potential association between treatment types and the probability of local recurrence and/or metastasis.

3 | RESULTS

3.1 | Demographics

One-hundred and fifty-five client-owned dogs were enrolled, of which 61 were female (46 spayed and 15 intact) and 94 were male (26 castrated and 68 intact). The mean and the median ages at presentation were 11.3 and 12.0 years, respectively (range 4-17 years); the mean and the median weights were 22.0 and 21.0 Kg, respectively (range 2-55 kg; Table 1). Approximately one third of the dogs were mixed breeds (53/155, 34.2%) while the remaining dogs (102/155, 65.8%) belonged to 36 different pure breeds. In particular, there were Cocker Spaniels (13 dogs), Golden Retrievers (12 dogs), German Shepherds (8 dogs), 5 each of Dachshunds and Yorkshire Terriers, 4 each of Beagles, Dwarf Schnauzers, Labrador Retrievers and Pinschers, 3 each of Giant Schnauzers, Pekingese, Rottweilers and English Setters, with the remaining dogs belonging to 23 different breeds.

3.2 | Tumour location, clinical staging and adjuvant treatment

The COMM was localized at the level of the gum of the lower arcade in 56 dogs (36.1%), the gum of the upper arcade in 36 dogs (23.2%),

TABLE 1 Clinical characteristics of the dogs enrolled in the study

		Overall population (155)	Curative intent surgery (109)	Marginal surgery (46)
Age (Years)	Mean	11.3	11.6	10.7
	Median	12	12	11
	Range	4-17	4-17	5-14.5
Weight (kg)	Mean	22	21.3	23.7
	Median	21	19	24
	Range	2-55	2-52	3-55
Sex (%)	Female intact	15 (9.7%)	9 (8.3%)	6 (13%)
	Spayed	46 (29.7%)	31 (28.4%)	15 (32.6%)
	Male intact	68 (43.8%)	49 (45%)	19 (41.4%)
	Neutered	26 (16.8%)	20 (18.3%)	6 (13%)
Localisation (%)	Mandible	56 (36.1%)	40 (36.7%)	16 (34.8%)
	Maxilla	36 (23.2%)	26 (23.9%)	10 (21.8%)
	Cheek	22 (14.2%)	19 (17.4%)	3 (6.5%)
	Lip	21 (13.5%)	18 (16.5%)	3 (6.5%)
	Tongue	10 (6.5%)	0 (0%)	10 (21.8%)
	Palate	8 (5.2%)	6 (5.5%)	2 (4.3%)
	Tonsil	2 (1.3%)	0 (0%)	2 (4.3%)
Clinical stage (%)	Stage I	24 (15.5%)	19 (17.4%)	5 (10.9%)
	Stage II	54 (34.8%)	32 (29.4%)	22 (47.8%)
	Stage III	66 (42.6%)	50 (45.9%)	16 (34.8%)
	Stage IV	11 (7.1%)	8 (7.3%)	3 (6.5%)

the mucosa of the cheek in 22 dogs (14.2%), the mucosa of the lip in 21 dogs (13.5%), the tongue in 10 dogs (6.5%), the palatine mucosa in 8 dogs (5.2%), and the tonsil in 2 dogs (1.3%) (Table 1).

Curative intent surgery consisted of 45 mandibulectomies, 27 maxillectomies and 37 cheek/lip *en bloc* excisions with or without mucosal reconstruction or skin flap reconstructions or a combination of both.

Mandibular lymphadenectomies were performed in 135 dogs, in 42 cases bilaterally (in three, the medial retropharyngeal lymph nodes were also removed) while in 93 dogs only the ipsilateral mandibular lymph nodes were removed. In 20 dogs, the lymph nodes were evaluated using fine needle aspiration and cytological examination only. The overall metastatic rate at the level of the regional lymph nodes was 41.9% (65/155). In particular, 63/135 (46.7%) of the nodes surgically excised were histologically metastatic (20/42 [47.6%] bilaterally removed and 43/93 [46.2%] ipsilaterally removed); of the 20 cases in which only a cytological evaluation was performed, only 2 (10%) were metastatic. This allowed establishing the definitive postoperative tumour stage (parameter N of the TNM system).³⁸

Clinical staging identified 24 stage I (15.5%), 54 stage II (34.8%), 66 stage III (42.6%) and 11 stage IV (7.1%) COMMs (bilateral metastasis at the level of the regional lymph nodes only); stage IV COMMs with distant metastasis were excluded (Table 1).

Data regarding adjuvant treatment are summarized in Table 2. Eighty-two dogs underwent adjuvant DNA electrovaccination against CSPG4, 10 dogs received adjuvant radiotherapy, 40 dogs had

metronomic treatment based on piroxicam, cyclophosphamide and thalidomide, eight received standard chemotherapy (cisplatin in four dogs and carboplatin in other four dogs) while electrochemotherapy was used in five dogs (with bleomycin intravenous injection; Table 2).

3.3 | Histological evaluation and immunohistochemical characterization of COMMs

Histology of the excision margins identified 68 (43.9%) COMMs with non-infiltrated margins (67 curative intent and 1 marginal) and 43 (27.7%) COMMs with infiltrated margins (11 curative intent and 32 marginal); the excision margin status was unknown in 44 (28.4%) COMMs (31 curative intent and 11 marginal; Table 3).

The mitotic index was $\geq 4/10$ HPF in 102 COMMs, $< 4/10$ HPF in 23 COMMs and was not available in 30 COMMs. The Ki67 expression was $\geq 19.5\%$ in 83 COMMs, $< 19.5\%$ in 29 cases and not available in 43 COMMs (Table 3). Immunohistochemistry for CSPG4 was < 3 in 40 COMMs (26%); the dogs bearing this COMM were only operated and not vaccinated.

3.4 | Follow-up and statistical data

One-hundred and nine dogs (70.3%) experienced progressive disease, of which 41 (37.6%) had a local recurrence only, 23 (21.1%) both a

TABLE 2 Adjuvant therapy used in the dogs enrolled in the study

	Overall population (155)	Curative intent surgery (109)	Marginal surgery (46)
Anti-CSPG4 electrovaccination	82 (52.9%)	51 (46.8%)	31 (67.4%)
Metronomic chemotherapy	40 (25.8%)	22 (20.2%)	18 (39.1%)
EV chemotherapy	8 (5.2%)	7 (6.4%)	1 (2.2%)
Radiation therapy	10 (6.5%)	5 (4.6%)	5 (10.9%)
Electrochemotherapy	5 (3.2%)	3 (2.7%)	2 (4.4%)

TABLE 3 Histological and immunohistochemical parameters of canine oral malignant melanoma present in the study

		Overall population (155)	Curative Intent Surgery (109)	Marginal Surgery (46)
Margins	Not infiltrated	68 (43.9%)	67 (61.5%)	1 (2.2%)
	Infiltrated	43 (27.7%)	11 (10.1%)	32 (69.6%)
	Unknown	44 (28.4%)	31 (28.4%)	13 (28.2%)
Mitotic index (MI)	≥4/10 HPF	102 (65.8%)	64 (58.7%)	38 (82.6%)
	<4/10 HPF	23 (14.8%)	17 (15.6%)	6 (13.0%)
	Unknown	30 (19.4%)	28 (25.7%)	2 (4.4%)
Ki67	≥19,5	83 (53.6%)	54 (49.5%)	29 (63.0%)
	<19,5	29 (18.7%)	16 (14.7%)	13 (28.3%)
	Unknown	43 (27.7%)	39 (35.8%)	4 (8.7%)

TABLE 4 Follow-up of the dogs enrolled in the study

		Local recurrence	Distant metastasis (lung)	Both metastasis and local recurrence
Overall population (155)	Alive (14)	1 (7.1%)	3 (21.4%)	0 (0.0%)
	COMM-related Death (85)	27 (31.8%)	36 (42.3%)	22 (25.9%)
	Unrelated death (50)	11 (22.0%)	6 (12.0%)	1 (2.0%)
	Lost to follow-up (6)	2 (33.3%)	0 (0.0%)	0 (0.0%)
Curative intent surgery (109)	Alive (12)	1 (8.3%)	2 (16.7%)	0 (0.0%)
	COMM-related death (57)	22 (38.6%)	25 (43.9%)	10 (17.5%)
	Unrelated death (36)	7 (19.4%)	2 (5.6%)	1 (2.8%)
	Lost to follow-up (4)	1 (25%)	0 (0.0%)	0 (0.0%)
Marginal surgery (46)	Alive (2)	0 (0.0%)	1 (50.0%)	0 (0.0%)
	COMM-related death (28)	5 (17.8%)	11 (39.3%)	12 (42.9%)
	Unrelated death (14)	4 (28.6%)	4 (28.6%)	0 (0.0%)
	Lost to follow-up (2)	1 (50.0%)	0 (0.0%)	0 (0.0%)

local recurrence and distant metastasis, and 45 (41.3%) distant metastases only (Table 4). At the end of the study, 14 (9.0%) dogs were still alive (range 386-2632 days) while 135 (87.1%) had died, 85 (62.9%) of which from COMM-related causes, and 6 (3.9%) were lost to follow-up.

When the dogs were divided based on the type of surgery, 109 dogs had undergone a curative intent (group 1, 70.3%) and 46 dogs a marginal (group 2, 29.7%) excision. The MST in groups 1 and 2 was 594 (range 46-2632 days) and 458 days (range 149-1063 days), respectively; no statistical difference was found ($P = .57$, Figure 1). The DFI in groups 1 and 2 was 232 (range

22-2632 days) and 183 days (range 13-1049 days), respectively; a statistical difference was found ($P = .008$, Figure 2).

Since many dogs underwent adjuvant anti-CSPG4 DNA electrovaccination, they were additionally subdivided with the aim of verifying how much the immunological treatment had impacted the outcomes. Eighty-two dogs (52.9%) underwent anti-CSPG4 DNA electrovaccination, of which 51 had curative intent surgery (group 3, 62.2%) and 31 a marginal resection (group 4, 37.8%). The MST in groups 3 and 4 was 1333 days (range 78-2632 days) and 470 days (range 187-1063 days), respectively; a statistical difference was found ($P = .03$, Figure 3). The DFI in Groups 3 and 4 was 324 (range




FIGURE 1 Groups 1 and 2. Median survival time (MST) for curative intent vs marginal surgery




FIGURE 2 Groups 1 and 2. Disease-free interval (DFI) for curative intent vs marginal surgery




FIGURE 3 Groups 3 and 4. Median survival time (MST) for curative intent vs marginal surgery in vaccinated dogs

37-2632 days) and 184 days (range 13-1049 days), respectively, with a significant difference between the two groups ($P = .008$, Figure 4).

The survival and disease-free rates at 6, 12, 18 and 24-months are reported in Table 5.

No association between the type of surgical excision performed and the occurrence of local recurrence, either in the entire canine population ($P = .48$) or in the dogs receiving the anti-CSPG4 DNA




FIGURE 4 Groups 3 and 4. Disease-free interval (DFI) for curative intent vs marginal surgery in vaccinated dogs

electrovaccination ($P = .49$) was demonstrated. No association was also found when the histology of the excision margins was compared with the outcome ($P = .18$). Instead, a significant association was found when the comparison was between the type of surgical excision (curative intent vs marginal) and progressive disease (local recurrence, metastasis only or recurrence plus distant metastasis) in both the overall population ($P = .03$) and in vaccinated dogs ($P = .02$). Finally, a significant association was found in the vaccinated dogs between the status of the histological excision margins and local recurrence ($P = .04$; Table 6).

4 | DISCUSSION

This retrospective study describes 155 dogs with COMMs treated with surgery, of which 82 dogs also received adjuvant anti-CSPG4 DNA electrovaccination. Compared with the existing literature, no relevant difference regarding age, breed, sex, weight and site of growth of the COMM was found in this population of dogs or among the groups.^{1-3,39}

The dogs included in the study were first divided into two groups, the first including dogs which had undergone curative intent surgery, such as mandibulectomy, maxillectomy or lip/cheek *en bloc* resection, followed, if required, by plastic reconstruction while the second group included those dogs which had undergone a marginal excision only, with no locally curative intent. Primary COMMs of the tongue and tonsils were also included in the second group. The goal of this division was to look for a potential statistical difference in outcome between these two groups of dogs.

The evaluation of these two groups did not reveal any significant difference in terms of Ki67 expression, MI and clinical stage, thus confirming a uniform distribution of the prognostic indicators reported.^{5,6} The MST in group 1 was longer than in group 2; however, no significant difference was found ($P = .57$). Instead, significance was demonstrated when the DFI of these two groups was evaluated ($P = .008$). It should be noted that the MST recorded in both groups 1 and 2 was superior to that reported in the study of Boston et al. (2014) in which

TABLE 5 Survival in months and DFI rate

	Months	Overall population (155)		Vaccinated dogs (82)	
		Curative intent surgery (109)	Marginal surgery (46)	Curative intent surgery (51)	Marginal surgery (31)
Survival rate	≥6	78.9%	95.6%	94.1%	100%
	≥12	51.1%	65.2%	72.5%	74.2%
	≥18	39.8%	35.3%	54%	40%
	≥24	28.1%	20%	35.5%	23.3%
DFI rate	≥6	65.1%	52.2%	72.5%	58%
	≥12	37.6%	21.7%	43.1%	22.6%
	≥18	25.9%	11.1%	30%	16.6%
	≥24	22.3%	6.7%	24.4%	10%

TABLE 6 Fisher's Exact test

	Curative intent surgery	Marginal surgery	P value	Clear margins	Infiltrated margins	P value
Overall population (155)						
Local recurrence	43 (39.4%)	21 (45.7%)	.48	28 (41.2%)	21 (48.8%)	.44
No recurrence	66 (60.6%)	25 (54.3%)		40 (58.8%)	22 (51.2%)	
Total	109	46		68 ^a	43 ^a	
Progressive disease	71 (65.1%)	38 (82.6%)	.03	47 (69.1%)	35 (81.4%)	.18
Stable disease	38 (34.9%)	8 (17.4%)		21 (30.9%)	8 (18.6%)	
Total	109	46		68 ^a	43 ^a	
Vaccinated dogs (82)						
Local recurrence	23 (45.1%)	17 (54.8%)	.49	20 (51.3%)	14 (82.4%)	.04
No recurrence	28 (54.9%)	14 (45.2%)		19 (48.7%)	3 (17.6%)	
Total	51	31		39 ^a	17 ^a	
Progressive disease	32 (62.8%)	27 (87.1%)	.02	27 (69.2%)	16 (94.1%)	.08
Stable disease	19 (37.6%)	4 (12.9%)		12 (30.8%)	1 (2.9%)	
Total	51	31		39 ^a	17 ^a	

Note: Associations between type of surgery/histological margins and the probability of local recurrence and/or progressive disease. Bold values are for those that are statistically significant

^aUnknown margins were not considered.

a large proportion of dogs were only operated on (MST of 352 days), and the use of different adjuvant therapies did not substantially change the outcome (MST of 335 days)¹⁵; it was however lower when compared with the results of the study of Tuohy et al. (2014) in which the MST was 723 days.⁴⁰ In the latter study, however, 74.3% of the COMMs were stages I and II (51.4% and 22.9% respectively), and only 20% were stages III and IV (18.6% and 1.4% respectively) while, in the present study, 50.3% of COMMs were stages I and II and 49.7% were stages III and IV (Table 1). The elevated number of higher stages of COMMs in the present population may explain this difference.⁴⁰

An important variable in this study was that many of the dogs in both group 1 and group 2 also underwent anti-CSPG4 DNA electrovaccination, which had already demonstrated to be able to increase both MST and DFI in COMMs.²⁷⁻²⁹ The authors' previous and ongoing studies have demonstrated the high expression and prevalence of the CSPG4 antigen in COMMs.^{27-29,36,37} The CSPG4 antigen has several interesting features ie high expression in the cell

membranes of neoplastic cells and low expression in the cells of healthy tissues as well as playing a key role in multiple tumourigenic processes.³⁶ Authors believe that these features make this molecule an ideal target in COMMs; DNA vaccination has been demonstrated to be safe in companion animals and effective in inducing a specific humoral and cellular response which could be long lasting.^{25,26,41,42} All these factors prompted the Authors to investigate the anti-CSPG4 DNA vaccination as an adjuvant option in treating COMM patients.^{27,28} Both the latter studies and the ongoing clinical trials have revealed the ability of anti-CSPG4 DNA electrovaccination to induce a significant antibody response capable of binding the antigen and likely inducing its down-modulation, impairing its tumourigenic function.²⁷⁻²⁹ and unpublished data

The rate of CSPG4 expression at immunohistochemistry in this series of dogs was not prognostic, as also already previously reported.²⁷ Additionally, when not vaccinated dogs were compared based on the cut-off value of CSPG4, that is, < 3 vs ≥ 3, there was no

significant difference regarding the MST (280 days vs 320 days [$P = .57$]).

In order to avoid any potential confounding elements in evaluating the impact of the two different surgical approaches (curative intent vs marginal) on the outcome, only vaccinated dogs receiving a curative intent (group 3) or a marginal (group 4) surgical excision were compared. Analysis showed a significant difference in both MST ($P = .03$) and DFI ($P = .008$), thus emphasizing the role of local surgical control in dogs subsequently treated with anti-CSPG4 electrovaccination in an attempt to also improve systemic control.

This study had some limitations. First of all, albeit this study dealt with COMMs treated in a single institution, it was a retrospective study which spanned a wide period of time during which imaging procedures to detect systemic metastases progressively changed (from three view X-rays of the thorax and abdominal ultrasound to total body CT scan), the latter being the most used in recent years; even the procedures for histological evaluation of the excision margins have been progressively improved. It should be noted that the histological evaluation of the excision margins was not available in 44/155 (28.4%) cases.

The second issue was relative to the evaluation of the regional lymph node status. In the past, this evaluation was based on cytology only or on its/their removal only when enlarged; recently it has been shown that this method does not reliably determine the N parameter of the TNM staging system.^{9,43} Currently, lymph node staging is based on their surgical removal and histologic examination, regardless of size and shape; in addition, more accurate imaging techniques, addressed to identifying either the regional or, more specifically, the sentinel lymph nodes, have been implemented.⁴⁴⁻⁵⁰ According to this, some of the dogs in the present study had undergone cytology only (older cases), others ipsilateral mandibular lymph node excision, others ipsilateral mandibular and medial retropharyngeal lymph node excision, and, more lately, bilateral and medial retropharyngeal lymph node excision. At present, the latter is the procedure which the authors routinely perform for COMM. Finally, the results of the cytological vs histological evaluation of the regional lymph nodes reported herein would indicate that histology appears to be more accurate than cytology in establishing the lymph node status (10% of the lymph nodes examined cytologically vs over 40% in those examined histologically).

The above limitations may have underestimated the tumour clinical stage, especially of the older cases but, on the other hand, this should be considered favourably when compared with the most recent retrospective studies.^{15,40}

An important difference between the vaccinated (vaccination is still a clinical trial approved by the Italian Ministry of Health) and not vaccinated dogs is the closer monitoring of the former. As a consequence, local recurrences, systemic metastasis or both may have been diagnosed later in not vaccinated dogs compared with vaccinated dogs. Therefore, the DFI in not vaccinated dogs may have been overestimated. However, this unequal follow-up does not influence the overall survival data.

At present, the authors do not have any specific data to present regarding metronomic therapy. They strongly believe that this would require a clinical trial addressed only to the evaluation of its efficacy.

This variable was very difficult to monitor; however, it may be said from an empirical point of view that this treatment was capable, likely together with electrovaccination, of stabilizing the disease in many cases, apparently avoiding the rapid progression of metastasis of COMM. However, additional studies on this treatment are warranted.

It can be concluded that a curative intent surgical approach, when feasible, is advisable in an attempt to prolong both the DFI and survival. The positive association between the type of surgery and the outcome confirmed this aspect; an association was also found when the histological status of the excision margins was considered in the vaccinated dogs; however, this was not the case in the overall population. The latter result should be considered cautiously as the histological evaluation of the excision margins was not available in all cases. Finally, it can also be concluded that adjuvant anti-CSPG4 DNA electrovaccination may additionally improve the outcome. Therefore, in the authors' experience a curative intent surgical procedure plus an adjuvant anti-CSPG4 DNA electrovaccination represented a valid therapeutic approach for COMM when considering MST, DFI, survival time and DFI rates.

CONFLICT OF INTEREST

The authors declare no conflicts of interest associated with the article.

DATA AVAILABILITY STATEMENT

Encourages Data Sharing

ORCID

Mariateresa Camerino  <https://orcid.org/0000-0003-2850-6794>

Federica Cavallo  <https://orcid.org/0000-0003-4571-1060>

Sara Del Magno  <https://orcid.org/0000-0002-2900-6989>

Raffaella De Maria  <https://orcid.org/0000-0002-7028-2280>

Paolo Buracco  <https://orcid.org/0000-0002-0181-0887>

REFERENCES

- Liptak JM, Lascelles BDX. Oral tumors. In: Kudnig ST, Séguin B, eds. *Veterinary Surgical Oncology*. 1st ed. Ames: Wiley-Blackwell; 2012: 119-177.
- Bergman PJ, Laura ES, Kent MS. Melanoma. In: Vail DM, Thamm DH, Liptak JM, eds. *Withrow & Mac Ewen's Small Animal Clinical Oncology*. 6th ed. St. Louis: Elsevier; 2019:367-381.
- Liptak JM. Oral tumors. In: Vail DM, Thamm DH, Liptak JM, eds. *Withrow and MacEwen's Small Animal Clinical Oncology*. 6th ed. St. Louis: Elsevier; 2020:432-448.
- Spangler WL, Kass PH. The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. *Vet Pathol*. 2006;43(2):136-149.
- Bergin IL, Smedley RC, Esplin DG, Spangler WL, Kiupel M. Prognostic evaluation of Ki67 threshold value in canine oral melanoma. *Vet Pathol*. 2011;48(1):41-53.
- Smedley RC, Spangler WL, Esplin DG, et al. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. *Vet Pathol*. 2011;48(1):54-72.
- Iussich S, Maniscalco L, Di Sciuva A, et al. PDGFRs expression in dogs affected by malignant oral melanomas: correlation with prognosis. *Vet Comp Oncol*. 2017;15(2):462-469.
- Nishiya AT, Massoco CO, Felizzola CR, et al. Comparative aspects of canine melanoma. *Vet Sci*. 2016;3(1):7.

9. Williams LE, Packer RA. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987–2001). *J Am Vet Med Assoc.* 2003;222:1234–1236.
10. Culp WT, Ehrhart N, Withrow SJ, et al. Results of surgical excision and evaluation of factors associated with survival time in dogs with lingual neoplasia: 97 cases (1995–2008). *J Am Vet Med Assoc.* 2013;242:1392–1397.
11. Freeman KP, Hahn KA, Harris FD, King GK. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987–1997). *J Vet Intern Med.* 2003;17:96–101.
12. Proulx DR, Ruslander DM, Dodge RK, et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. *Vet Radiol Ultrasound.* 2003;44:352–359.
13. Boria PA, Murry DJ, Bennett PF, et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. *J Am Vet Med Assoc.* 2004;224(3):388–394.
14. Murphy S, Hayes AM, Blackwood L, Maglennon G, Pattinson H, Sparkes AH. Oral malignant melanoma - the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. *Vet Comp Oncol.* 2005;3(4):222–229.
15. Boston SE, Lu X, Culp WT, et al. Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001–2012). *J Am Vet Med Assoc.* 2014;245(4):401–407.
16. Kawabe M, Mori T, Ito Y, et al. Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006–2012). *J Am Vet Med Assoc.* 2015;247:1146–1153.
17. Cancedda S, Rohrer Bley C, Aresu L, et al. Efficacy and side effects of radiation therapy in comparison with radiation therapy and temozolomide in the treatment of measurable canine malignant melanoma. *Vet Comp Oncol.* 2016;14(4):e146–e115.
18. Turek M, LaDue T, Looper J, et al. Multimodality treatment including ONCEPT for canine oral melanoma: a retrospective analysis of 131 dogs. *Vet Radiol Ultrasound.* 2020;61(4):471–480.
19. Milevoj N, Tratar UL, Nemec A, et al. A combination of electrochemotherapy, gene electrotransfer of plasmid encoding canine IL-12 and cytoreductive surgery in the treatment of canine oral malignant melanoma. *Res Vet Sci.* 2019;122:40–49.
20. Nemec A, Milevoj N, Lamprecht Tratar U, Serša G, Čemažar M, Tozon N. Electroporation-based treatments in small animal veterinary oral and maxillofacial oncology. *Front Vet Sci.* 2020;7:575911.
21. Tellado MN, Maglietti FH, Michinski SD, Marshall GR, Signori E. Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome. *Radiol Oncol.* 2020;54(1):68–78.
22. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989–2000). *J Am Vet Med Assoc.* 2001;218(9):1444–1448.
23. Brockley LK, Cooper MA, Bennett PF. Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatin chemotherapy on survival. *N Z Vet J.* 2013;61(1):25–31.
24. Dank G, Rassnick KM, Sokolovsky Y, et al. Use of adjuvant carboplatin for treatment of dogs with oral malignant melanoma following surgical excision. *Vet Comp Oncol.* 2014;12(1):78–84.
25. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. *Clin Cancer Res.* 2003;9:1284–1290.
26. Grosenbaugh DA, Leard AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. *Am J Vet Res.* 2011;72:1631–1638.
27. Riccardo F, Iussich S, Maniscalco L, et al. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. *Clin Cancer Res.* 2014;20:3753–3762.
28. Piras LA, Riccardo F, Iussich S, et al. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination. *Vet Comp Oncol.* 2017;15(3):996–1013.
29. Tarone L, Barutello G, Iussich S, et al. Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. *Cancer Immunol Immunother.* 2019;68:1839–1853.
30. Ottnod JM, Smedley RC, Walshaw R, Hauptman JG, Kiupel M, Obradovich JE. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. *Vet Comp Oncol.* 2013;11:219–229.
31. McLean JL, Lobetti RG. Use of the melanoma vaccine in 38 dogs: 2015; The South African experience. *J S Af Vet Ass.* 2015;86:1246.
32. Treggiari E, Grant JP, North SM. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. *J Vet Med Sci.* 2016;78(5):845–850.
33. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. *Crit Rev Immunol.* 2004;24(4):267–296.
34. Yang J, Price MA, Neudauer CL, et al. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. *J Cell Biol.* 2004;165(6):881–891.
35. Price MA, Colvin Wanshura LE, Yang J, et al. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. *Pigment Cell Melanoma Res.* 2011;24(6):1148–1157.
36. Rolih V, Barutello G, Iussich S, et al. CSPG4: a prototype oncoantigen for translational immunotherapy studies. *J Transl Med.* 2017;15(1):151.
37. Mayayo SL, Prestigio S, Maniscalco L, et al. Chondroitin sulfate proteoglycan 4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. *Vet J.* 2011;190:e26–e30.
38. Owen LN, ed. *World Health Organization TNM Classification of Tumors in Domestic Animals.* 1st. ed. Geneva, WHO; Veterinary Public Health Unit & WHO Collaborating Center for Comparative Oncology; 1980.
39. Ramos-Vara JA, Beissenherz ME, Miller MA, et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. *Vet. Pathol.* 2000;37:597–608.
40. Tuohy JL, Selmic LE, Worley DR, Ehrhart NP, Withrow SJ. Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998–2011). *J Am Vet Med Assoc.* 2014;245(11):1266–1273.
41. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. *Vaccine.* 2006;24(21):4582–4585.
42. Impellizeri JA, Ciliberto G, Aurisicchio L. Electro-gene-transfer as a new tool for cancer immunotherapy in animals. *Vet Comp Oncol.* 2014;12(4):310–318.
43. Grimes J, Matz B, Christopherson P, et al. Agreement between cytology and histopathology for regional lymph node metastasis in dogs with melanocytic neoplasms. *Vet Pathol.* 2017;54(4):579–587.
44. Herring ES, Smith MM, Robertson JL. Lymph node staging of oral and maxillofacial neoplasms in 31 dogs and cats. *J Vet Dent.* 2002;19(3):122–126.
45. Green K, Boston SE. Bilateral removal of the mandibular and medial retropharyngeal lymph nodes through a single ventral midline incision for staging of head and neck cancers in dogs: a description of surgical technique. *Vet Comp Oncol.* 2017;15(1):208–214.
46. Skinner OT, Boston SE, Souza CHM. Patterns of lymph node metastasis identified following bilateral mandibular and medial retropharyngeal

- lymphadenectomy in 31 dogs with malignancies of the head. *Vet Comp Oncol.* 2017;15:881-889.
47. Skinner OT, Boston SE, Giglio RF, Whitley EM, Colee JC, Porter EG. Diagnostic accuracy of contrast-enhanced computed tomography for assessment of mandibular and medial retropharyngeal lymph node metastasis in dogs with oral and nasal cancer. *Vet Comp Oncol.* 2018; 16(4):562-570.
48. Wainberg SH, Oblak ML, Giuffrida MA. Ventral cervical versus bilateral lateral approach for extirpation of mandibular and medial retropharyngeal lymph nodes in dogs. *Vet Surg.* 2018;47(5): 629-633.
49. Grimes JA, Mestrinho LA, Berg J, et al. Histologic evaluation of mandibular and medial retropharyngeal lymph nodes during staging of oral malignant melanoma and squamous cell carcinoma in dogs. *J Am Vet Med Assoc.* 2019;254(8):938-943.
50. Odenweller PH, Smith MM, Taney KG. Validation of regional lymph node excisional biopsy for staging oral and maxillofacial malignant neoplasms in 97 dogs and 10 cats (2006–2016). *J Vet Dent.* 2019;36 (2):97-103.

How to cite this article: Giacobino D, Camerino M, Riccardo F, et al. Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases. *Vet Comp Oncol.* 2021;1–10. <https://doi.org/10.1111/vco.12690>